星空传媒91传媒制片厂|明星换脸五级片|麻豆传媒映画女演员王茜|麻豆在传媒在线|九九国产|91制片厂在线观看一二区|夜夜草视频|四虎影院在线播放|国产精品亚洲国际在线看|大象传媒国产第一页,麻豆映画传媒有免费的吗,91制片厂安卓,亚洲成年人精选,91你懂得国产,爱豆视传媒短视频免费,免费一级片

On the morning of October 8, Ma Zhenkun, founder and president of TenNor Therapeutics, stepped into the Zhongshan Life Science Park with his colleagues to inspect the implementation of the company's project.

In 2013, after resigning from the TB Alliance, Ma Zhenkun returned to China and founded TenNor Therapeutics. The company focuses on diseases related to bacterial infections and metabolism as well as on new drug research and development. Currently, three of its products have entered the later clinical trial stage.

According to a publication in a top global comprehensive medical journal, the world's first-in-class innovative drug Rifasutenizol (TNP-2198) developed by TenNor Therapeutics is the first in the world over 30 years specifically developed for the treatment of Helicobacter pylori. This product is expected to overcome the challenge of antibiotic resistance and provide a novel Chinese solution for Helicobacter pylori infection.

In September of this year, TenNor Therapeutics signed an investment agreement with Zhongshan Venture Capital, a subsidiary of Zhongshan Investment Holdings, to establish a project in Zhongshan. The financing funds will be used for the commercialization of TNP-2198 and advancing the R&D and clinical trials of TenNor Therapeutics' other new drug products.

According to the agreement, TenNor Therapeutics will settle its project in the Zhongshan Life Science Park. At least 300 million yuan will be invested in the construction of a production base for core pipelines with a settlement center.